Companies › Greenwich LifeSciences
1 active drug program in 1 registered trial: 1 Phase 3; Oncology; next expected readout Dec 2031.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| GLSI-100 HER2/Neu peptide vaccine with GM-CSF adjuvant | ERBB2 | Phase 3 | Breast Cancer | Dec 2031 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT05232916 | GLSI-100 | Phase 3 | Breast Cancer | Oncology | Dec 2031 |
Cash of $9m on 2026-06-30; operating cash outflow about $13m a year; runway about 8 months at that burn, to Feb 2027; 0 of 1 coming phase 2-3 readouts fall inside that runway
Shanghai Miracogen 3D Medicines (Sichuan) PharmaEssentia Partner Therapeutics Abscint NV/SA
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.